Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW

Thank you in advance for your participation.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:39:49 ON 19 MAY 2006

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 10:40:38 ON 19 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 18, 2006 (20060518/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 10:40:45 ON 19 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 10:40:53 ON 19 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2006 HIGHEST RN 884905-05-9
DICTIONARY FILE UPDATES: 18 MAY 2006 HIGHEST RN 884905-05-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s creatine/cn
L1 1 CREATINE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 57-00-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Creatine (8CI)**
OTHER NAMES:
CN Cosmocair C 100
CN Methylguanidoacetic acid
CN N-Methyl-N-guanylglycine
CN NSC 8752
CN Phosphagen
FS 3D CONCORD
MF C4 H9 N3 O2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PROMT, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6238 REFERENCES IN FILE CA (1907 TO DATE)
129 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6248 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s creatine phosphate/cn
L2 1 CREATINE PHOSPHATE/CN

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 67-07-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Sarcosine, N-(phosphonoamidino)- (8CI)
OTHER NAMES:
CN **Creatine phosphate**
CN Creatinephosphoric acid
CN N-(Phosphonoamidino)sarcosine
CN N-Phosphorocreatine
CN N-Phosphorylcreatine

CN Phosphocreatine
CN Phosphorylcreatine
FS 3D CONCORD
MF C4 H10 N3 O5 P
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PROMT, PROUSDDR, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7250 REFERENCES IN FILE CA (1907 TO DATE)
24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7256 REFERENCES IN FILE CAPLUS (1907 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.20	14.68

FILE 'CAPLUS' ENTERED AT 10:41:58 ON 19 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 May 2006 VOL 144 ISS 22
FILE LAST UPDATED: 18 May 2006 (20060518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1
L3 6248 L1

=> s l1 full
L4 6248 L1

=> s l2 full
L5 7256 L2

=> s (l4 or l5) and (glutamate excitotoxity or benoquinone or nicotinamide or spin traps or growth factor or asprin or nitric oxide synthase or cyclooxygenase 2 or ICE or neuroimmunophilis or acetylcysteine or antioxidants or lipoic acid or cofactors or riboflavin or CoQ10)

```
 101271 GLUTAMATE
   1106 GLUTAMATES
 101673 GLUTAMATE
          (GLUTAMATE OR GLUTAMATES)
     10 EXCITOTOXITY
      2 GLUTAMATE EXCITOTOXITY
          (GLUTAMATE(W)EXCITOTOXITY)
      3 BENOQUINONE
  21498 NICOTINAMIDE
    405 NICOTINAMIDES
  21607 NICOTINAMIDE
          (NICOTINAMIDE OR NICOTINAMIDES)
 388858 SPIN
  27833 SPINS
 397482 SPIN
          (SPIN OR SPINS)
  52780 TRAPS
    794 SPIN TRAPS
          (SPIN(W)TRAPS)
1264765 GROWTH
   4332 GROWTHS
1266975 GROWTH
          (GROWTH OR GROWTHS)
 964211 FACTOR
 864846 FACTORS
1520814 FACTOR
          (FACTOR OR FACTORS)
 181289 GROWTH FACTOR
          (GROWTH(W)FACTOR)
     19 ASPRIN
 168834 NITRIC
      3 NITRICS
 168837 NITRIC
          (NITRIC OR NITRICS)
1650577 OXIDE
 340086 OXIDES
1747239 OXIDE
          (OXIDE OR OXIDES)
  95524 SYNTHASE
   5552 SYNTHASES
  96511 SYNTHASE
          (SYNTHASE OR SYNTHASES)
  31243 NITRIC OXIDE SYNTHASE
          (NITRIC(W)OXIDE(W)SYNTHASE)
  24882 CYCLOOXYGENASE
    835 CYCLOOXYGENASES
  25088 CYCLOOXYGENASE
          (CYCLOOXYGENASE OR CYCLOOXYGENASES)
8739174 2
   9878 CYCLOOXYGENASE 2
          (CYCLOOXYGENASE(W)2)
 109684 ICE
   1815 ICES
 110182 ICE
          (ICE OR ICES)
      0 NEUROIMMUNOPHILIS
   6331 ACETYLCYSTEINE
     10 ACETYLCYSTEINES
   6333 ACETYLCYSTEINE
          (ACETYLCYSTEINE OR ACETYLCYSTEINES)
  95966 ANTIOXIDANTS
   3708 LIPOIC
4148725 ACID
1523480 ACIDS
4638801 ACID
          (ACID OR ACIDS)
   3665 LIPOIC ACID
          (LIPOIC(W)ACID)
```

```
        10539 COFACTORS
        13435 RIBOFLAVIN
           63 RIBOFLAVINS
        13445 RIBOFLAVIN
                (RIBOFLAVIN OR RIBOFLAVINS)
          831 COQ10
L6        454 (L4 OR L5) AND (GLUTAMATE EXCITOTOXITY OR BENOQUINONE OR NICOTIN
              AMIDE OR SPIN TRAPS OR GROWTH FACTOR OR ASPRIN OR NITRIC OXIDE
              SYNTHASE OR CYCLOOXYGENASE 2 OR ICE OR NEUROIMMUNOPHILIS OR ACETY
              LCYSTEINE OR ANTIOXIDANTS OR LIPOIC ACID OR COFACTORS OR RIBOFLAV
              IN OR COQ10)

=> s l6 and parkinson?
        23582 PARKINSON?
L7         14 L6 AND PARKINSON?

=> d ibib abs hitstr tot

L7   ANSWER 1 OF 14  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2006:216951  CAPLUS
DOCUMENT NUMBER:         144:267302
TITLE:                   Use of methyl pyruvate or methyl pyruvic acid for the
                         treatment of diseases of the nervous system and for
                         protecting a human central nervous system against
                         neuronal degeneration caused by defective
                         intracellular energy production.
INVENTOR(S):             Antosh, Stanley Charles; Meduri, Anthony J.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 10 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 2006052448         A1    20060309    US 2004-711255          20040904
     WO 2006028948         A2    20060316    WO 2005-US31249         20050831
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       US 2004-711255      A  20040904
AB   The present invention relates to the use of Me pyruvic acid (a Me ester of
     pyruvic acid) and/or Me pyruvate (Me pyruvate is the ionized form of Me
     pyruvic acid) for the purpose of treating diseases of the nervous system
     and/or to prevent against neuronal degeneration due to defective
     intracellular energy production  Me pyruvate compds. can be used as
     therapeutically effective agents against a variety of diseases of the
     nervous system such as diabetic and toxic neuropathies, peripheral nervous
     system diseases, Alzheimer disease, Parkinson's disease, stroke,
     Huntington's disease, amyotropic lateral sclerosis, motor neuron disease,
     traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination
     disorders, or cellular disorders which interfere with the energy metabolism of
     neurons and mitochondrial diseases.  Use of Me pyruvate and/or Me pyruvic
     acid can be effective when administered orally or infused on either a
     chronic and/or acute basis.  Treatment can be effective even when
     administered after the onset of an ischemic event that triggers
     neurodegeneration.  In the following text, the terms "methyl pyruvate, Me
```

pyruvate compds., Me pyruvic acid" are used interchangeably.

IT **57-00-1**, Creatine **57-00-1D**, Creatine, analogs
67-07-2, Creatine phosphate **67-07-2D**,
N-Phosphorocreatine, analogs
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of Me pyruvate or Me pyruvic acid for treatment of diseases of nervous system and neuronal degeneration caused by defective intracellular energy production and combination with other agents)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:147331 CAPLUS
DOCUMENT NUMBER: 144:219283
TITLE: Physiologically acceptable composition containing alpha-**lipoic acid**, creatine, and a phosphatide
INVENTOR(S): Schuhbauer, Hans; Jaeger, Ralf; Purpura, Martin
PATENT ASSIGNEE(S): Bioghurt Biogarde Gmbh & Co. KG, Germany
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015774	A1	20060216	WO 2005-EP8375	20050802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

DE 102004038155 A1 20060316 DE 2004-102004038155 20040806
PRIORITY APPLN. INFO.: DE 2004-102004038155A 20040806

AB Disclosed is a novel physiol. acceptable composition substantially containing α- **lipoic acid**, creatine and a phosphatide and/or one of the suitable derivs. thereof. Said composition preferably contains 0.01 to 80 % by weight of the **lipoic acid** component, 1.0 to 99.9 % of the creatine component, and 0.01 to 80 % by weight of the phosphatide component and is used mainly for slowing down degenerative and particularly progressive modifications of the brain. Forms of administration such as food supplements, food, beverages, medicaments, cosmetics are particularly suitable. In general, the disclosed composition is used in individual doses ranging between 10 mg and 10 g. The inventive combination makes it possible to obtain results which additively exceed the effects of the individual compds. while representing cases of application that were unknown for the individual compds. Thus a gelatin capsule contained (mg): (±)-α- **lipoic acid** 60; creatine monohydrate 400; phosphatidylserine 40.

IT **57-00-1**, Creatine **67-07-2**, Creatine phosphate
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(physiol. acceptable composition containing alpha-**lipoic acid**, creatine, and a phosphatide)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1310905 CAPLUS
DOCUMENT NUMBER: 144:45513
TITLE: Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same, and uses thereof
INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S. Ser. No. 906,303.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2005276872	A1	20051215	US 2005-117760	20050427
US 2003091669	A1	20030515	US 2001-944805	20010831
US 6616943	B2	20030909		
WO 2003017919	A2	20030306	WO 2002-IB4750	20020828
WO 2003017919	A3	20040722		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004146591	A1	20040729	US 2003-471384	20030904
WO 2005037200	A2	20050428	WO 2004-US33359	20041008
WO 2005037200	A3	20050616		
WO 2005037200	C1	20050901		
WO 2005037200	B1	20051006		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005063273	A1	20050714	WO 2004-US43465	20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005220910	A1	20051006	US 2005-906303	20050214
WO 2006029221	A2	20060316	WO 2005-US31900	20050907

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2001-944805	A2	20010831
WO 2002-IB4750	W	20020828
US 2003-471384	A2	20030904
US 2003-509851P	P	20031009
US 2003-532101P	P	20031223
US 2004-607858P	P	20040907
US 2004-613811P	P	20040927
US 2004-617379P	P	20041008
WO 2004-US33359	A2	20041008
WO 2004-US43465	A2	20041223

US 2005-906303	A2	20050214
US 2005-117760	A	20050427
US 2005-675282P	P	20050427
US 2005-675284P	P	20050427
US 2005-131551	A	20050517

OTHER SOURCE(S): MARPAT 144:45513

AB This invention provides compns., methods and process of producing exts. and pure compds. from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, **Parkinson**'s, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compds. of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or/and 22, or/and linked to the sugar. The compds. of the present invention have various pharmaceutical and therapeutic applications.

IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Xanthoceras sorbifolia extract composition, isolated compds., preparation methods, and therapeutic use)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:369224 CAPLUS

DOCUMENT NUMBER: 142:423889

TITLE: Composition comprising Xanthoceras sorbifolia extracts, isolated compounds, preparation methods, and therapeutic use

INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun

PATENT ASSIGNEE(S): Pacific Arrow Limited, Peop. Rep. China

SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037200	A2	20050428	WO 2004-US33359	20041008
WO 2005037200	A3	20050616		
WO 2005037200	C1	20050901		
WO 2005037200	B1	20051006		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005063273 A1 20050714 WO 2004-US43465 20041223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005220910 A1 20051006 US 2005-906303 20050214
US 2005245470 A1 20051103 US 2005-117745 20050427
US 2005276872 A1 20051215 US 2005-117760 20050427
US 2005277601 A1 20051215 US 2005-131551 20050517
WO 2006029221 A2 20060316 WO 2005-US31900 20050907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2003-509851P	P	20031009
US 2003-532101P	P	20031223
US 2001-944805	A2	20010831
WO 2002-IB4750	W	20020828
US 2003-471384	A2	20030904
US 2004-607858P	P	20040907
US 2004-613811P	P	20040927
US 2004-617379P	P	20041008
WO 2004-US33359	A	20041008
WO 2004-US43465	A2	20041223
US 2005-906303	A2	20050214
US 2005-117745	A2	20050427
US 2005-117760	A	20050427
US 2005-675282P	P	20050427
US 2005-675284P	P	20050427
US 2005-131551	A	20050517

OTHER SOURCE(S): MARPAT 142:423889

AB The invention provides compns., methods and process of producing exts. from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for anticancer, preventing cerebral aging, improving memory, improving cerebral functions and curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, **Parkinson**'s disease and other diseases caused by cerebral dysfunction, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder and treating impotence and premature ejaculation. The invention provides compds. comprise a sugar, terepene, e.g. sapogenin, and a side chains at carbon 21 and 22, e.g. angeloyl groups. The compds. of the invention have various pharmaceutical and therapeutic applications.

IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Xanthoceras sorbifolia extract composition, isolated compds., preparation methods,

and therapeutic use)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:983902 CAPLUS
DOCUMENT NUMBER: 142:425007
TITLE: Caenorhabditis elegans MPP Model of **Parkinson**'s Disease for High-Throughput Drug Screenings
AUTHOR(S): Braungart, Evelyn; Gerlach, Manfred; Riederer, Peter; Baumeister, Ralf; Hoener, Marius C.
CORPORATE SOURCE: Pieris Proteolab AG, Freising-Weihenstephan, Germany
SOURCE: Neurodegenerative Diseases (2004), 1(4-5), 175-183
CODEN: NDEIA6; ISSN: 1660-2854
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The neurotoxin MPTP and its active metabolite MPP+ cause **Parkinson**'s disease (PD)-like symptoms in vertebrates by selectively destroying dopaminergic neurons in the substantia nigra. MPTP/MPP+ models have been established in rodents to screen for pharmacol. active compds. In addition to being costly and time consuming, these animal models are not suitable for large scale testings using compound libraries. The authors present a novel MPP+-based model for high-throughput screenings using the nematode Caenorhabditis elegans. Incubation of C. elegans with MPTP or its active metabolite MPP+ resulted in strong symptomatic defects including reduced mobility and increased lethality, and is correlated with a specific degeneration of the dopaminergic neurons. The phenotypic consequences of MPTP/MPP+ treatments were recorded using automated hardware and software for quantification. Incubation of C. elegans with a variety of pharmacol. active components used in PD treatment reduced the MPP+-induced defects. These data suggest that the C. elegans MPTP/MPP+ model can be used for the quant. evaluation of anti-PD drugs.
IT **57-00-1**, Creatine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Caenorhabditis elegans MPP model of **Parkinson**'s disease for high-throughput drug screenings)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:934313 CAPLUS
DOCUMENT NUMBER: 141:400910
TITLE: Medical composition for balancing bodily processes
INVENTOR(S): Bland, Jeffrey S.; Liska, Deann J.; Krumhar, Kim Carleton; Tripp, Matthew L.; Darland, Gary K.; Lerman, Robert H.; Lukaczer, Daniel O.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 352,388.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004220118	A1	20041104	US 2003-735526		20031211
US 2002192310	A1	20021219	US 2002-56858		20020123
US 2003190381	A1	20031009	US 2003-352388		20030127
PRIORITY APPLN. INFO.:			US 2001-265908P	P	20010202
			US 2002-56858	A2	20020123
			US 2002-352016P	P	20020125
			US 2002-432689P	P	20021211
			US 2003-352388	A2	20030127

AB Medical compns. and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed. A medical composition in the form of tablets for nutritional support of women with symptoms associated with hormone cycles contained vitamin A 2500 IU, vitamin D 200 IU, vitamin E 200 IU, vitamin K 40 mcg, vitamin B6 50 mg, vitamin B12 30 mcg, folic acid 800 mcg, isoflavones 100 mg, curcumin 200 mg, trimethylglycine 200 mg, resveretrol 2 mg, rosemary extract 200 mg, and chrysin 100 mg. The effects of the tablets was clin. studied in women.

IT **57-00-1**, Creatine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(medical composition for balancing bodily processes)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:949255 CAPLUS
DOCUMENT NUMBER: 140:210533
TITLE: Additive neuroprotective effects of creatine and a **cyclooxygenase 2** inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of **Parkinson**'s disease
AUTHOR(S): Klivenyi, Peter; Gardian, Gabrielle; Calingasan, Noel Y.; Yang, Lichuan; Beal, M. Flint
CORPORATE SOURCE: Department of Neurology and Neuroscience, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, 10021, USA
SOURCE: Journal of Molecular Neuroscience (2003), 21(3), 191-198
CODEN: JMNEES; ISSN: 0895-8696
PUBLISHER: Humana Press Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB There is evidence that both inflammatory mechanisms and mitochondrial dysfunction contribute to **Parkinson**'s disease (PD) pathogenesis. We investigated whether the **cyclooxygenase 2** (COX-2) inhibitor rofecoxib either alone or in combination with creatine could exert neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of PD in mice. Both rofecoxib and creatine administered alone protected against striatal dopamine depletions and loss of substantia nigra tyrosine hydroxylase immunoreactive neurons. Administration of rofecoxib with creatine produced significant additive neuroprotective effects against dopamine depletions. These results suggest that a combination of a COX-2 inhibitor with creatine might be a useful neuroprotective strategy for PD.

IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(additive neuroprotective effects of creatine and a **cyclooxygenase 2** inhibitor against dopamine depletion in mouse model of **Parkinson**'s disease)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:855794 CAPLUS
DOCUMENT NUMBER: 139:345938
TITLE: Combination therapy including **cyclooxygenase 2** (COX2) inhibitor(s) for the treatment of **Parkinson**'s disease
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003088958	A2	20031030	WO 2003-US11269		20030414
WO 2003088958	A3	20040819			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2481934	AA	20031030	CA 2003-2481934		20030414
AU 2003223579	A1	20031103	AU 2003-223579		20030414
US 2004034083	A1	20040219	US 2003-413348		20030414
EP 1494664	A2	20050112	EP 2003-719717		20030414
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003009259	A	20050209	BR 2003-9259		20030414
JP 2005528403	T2	20050922	JP 2003-585710		20030414
PRIORITY APPLN. INFO.:			US 2002-373311P	P	20020418
			WO 2003-US11269	W	20030414

OTHER SOURCE(S): MARPAT 139:345938
AB The invention discloses a method for treating, preventing, or inhibiting **Parkinson**'s disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective

amount
IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy including **cyclooxygenase 2** inhibitor for treatment of **Parkinson**'s disease)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:765720 CAPLUS
DOCUMENT NUMBER: 140:174175
TITLE: Targeting cellular energy production in neurological disorders
AUTHOR(S): Baker, Steven K.; Tarnopolsky, Mark A.
CORPORATE SOURCE: Department of Medicine, Neurology and Rehabilitation, McMaster University, Hamilton, ON, L8N 3Z5, Can.
SOURCE: Expert Opinion on Investigational Drugs (2003), 12(10), 1655-1679
CODEN: EOIDER; ISSN: 1354-3784
PUBLISHER: Ashley Publications Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The concepts of energy dysregulation and oxidative stress and their complicated interdependence have rapidly evolved to assume primary importance in understanding the pathophysiol. of numerous neurol. disorders. Therefore, neuroprotective strategies addressing specific bioenergetic defects hold particular promise in the treatment of these conditions (i.e., amyotrophic lateral sclerosis, Huntington's disease, **Parkinson**'s disease, Friedreich's ataxia, mitochondrial cytopathies and other neuromuscular diseases), all of which, to some extent, share the final common pathway' leading to cell death through either necrosis or apoptosis. Compds. such as creatine monohydrate and coenzyme Q10 offer substantial neuroprotection against ischemia, trauma, oxidative damage and neurotoxins. Miscellaneous agents, including α-**lipoic acid**, β-OH-β-methylbutyrate, **riboflavin** and **nicotinamide**, have also been shown to improve various metabolic parameters in brain and/or muscle. This review will highlight the biol. function of each of the above mentioned compds. followed by a discussion of their utility in animal models and human neurol. disease. The balance of this work will be comprised of discussions on the therapeutic applications of creatine and coenzyme Q10.
IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeting cellular energy production in neurol. disorders)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 330 THERE ARE 330 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:319452 CAPLUS

DOCUMENT NUMBER: 138:314630
TITLE: Orthomolecular sulfo-adenosylmethionine derivatives with antioxidant properties
INVENTOR(S): Wilburn, Michael D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078231	A1	20030424	US 2001-886612	20010622
PRIORITY APPLN. INFO.:			US 2001-886612	20010622
OTHER SOURCE(S):	MARPAT 138:314630			

GI



I

AB Disclosed are orthomol. sulfo-adenosylmethionine derivative compds., compns., and their uses for effecting a biol. activity in an animal, such as neurochem. activity; liver biol. activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compds. of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compds. of the present invention are I (R1 = H, C1-C10 alkyl, C2-C10 alkenyl or alkynyl, -C(O)R2; R2 = C1-C10 alkyl, C2-C10 alkenyl or alkynyl; Q = -C(NH3)C(O)AX, -C(COOH)NHX; A = O, N; X = a defined reaction product) or pharmaceutically acceptable salt, ester or solvate thereof. α-(S-adenosylmethionine)-O-tocopherol was prepared from N-Acetyl-S-benzyl-L-homocysteine, α-tocopherol, and 5'-O-p-Tolylsulfonyladenosine.

IT **57-00-1D**, Creatine, reaction products with S-adenosyl-L-methionine derivs. **67-07-2D**, Phosphocreatine, reaction products with S-adenosyl-L-methionine derivs.
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(orthomol. S-adenosyl-L-methionine derivs. with antioxidant properties)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:315166 CAPLUS
DOCUMENT NUMBER: 139:316285
TITLE: Bioenergetic approaches for neuroprotection in **Parkinson**'s disease
AUTHOR(S): Beal, M. Flint
CORPORATE SOURCE: Department of Neurology and Neuroscience, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
SOURCE: Annals of Neurology (2003), 53(Suppl. 3), S39-S48
CODEN: ANNED3; ISSN: 0364-5134
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. There is considerable evidence suggesting that mitochondrial dysfunction and oxidative damage may play a role in the pathogenesis of **Parkinson**'s disease (PD). This possibility has been strengthened by recent studies in animal models, which have shown that a selective inhibitor of complex I of the electron transport gene can produce an animal model that closely mimics both the biochem. and histopathol. findings of PD. Several agents are available that can modulate cellular energy metabolism and that may exert antioxidative effects. There is substantial evidence that mitochondria are a major source of free radicals within the cell. These appear to be produced at both the iron-sulfur clusters of complex I as well as the ubiquinone site. Agents that have shown to be beneficial in animal models of PD include creatine, coenzyme Q10, Ginkgo biloba, **nicotinamide**, and acetyl-L-carnitine. Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD. Similarly, coenzyme Q10 is also effective in animal models and has shown promising effects both in clin. trials of PD as well as in clin. trials in Huntington's disease and Friedreich's ataxia. Many other agents show good human tolerability. These agents therefore are promising candidates for further study as neuroprotective agents in PD.

IT **57-00-1**, Creatine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioenergetic approaches for neuroprotection in **Parkinson**'s disease)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:833099 CAPLUS
DOCUMENT NUMBER: 135:362605
TITLE: Nutritional preparation comprising ribose and folic acid and medical use thereof
INVENTOR(S): Hageman, Robert Johan Joseph; Smeets, Rudolf Leonardus Lodewijk; Verlaan, George
PATENT ASSIGNEE(S): N.V. Nutricia, Neth.
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085178	A1	20011115	WO 2001-NL349	20010508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6420342	B1	20020716	US 2000-566381	20000508
EP 1282426	A1	20030212	EP 2001-930315	20010508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003532679	T2	20031105	JP 2001-581831	20010508
US 2002183263	A1	20021205	US 2002-178736	20020625
US 6548483	B2	20030415		

PRIORITY APPLN. INFO.: US 2000-566381 A 20000508
WO 2001-NL349 W 20010508

AB Trauma, surgery, inflammation, subfertility, lactation problems, gut disorders, infant nutrition, cancer, arthritis and other joint problems, vascular problems and cardio- or cerebrovascular problems, ischemia, aging, impaired immune function, burns, sepsis, malnutrition, problems with liver or kidneys, malaria, cystic fibrosis, migraine, neurol. problems, respiratory infections, improvement of sports results, muscle soreness, drug intoxication and pain can be treated with a nutritional composition containing effective amts. of ribose and folic acid, optionally combined with other components such as niacin, histidine, glutamine, orotate, vitamin B6 and other components.

IT **57-00-1**, Creatine
RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional preparation comprising ribose and folic acid and medical use)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:659188 CAPLUS
DOCUMENT NUMBER: 131:281583
TITLE: Compositions containing a combination of a creatine compound and a neuroprotective compound for the treatment of nervous system diseases
INVENTOR(S): Kaddurah-Daouk, Rima; Beal, M. Flint
PATENT ASSIGNEE(S): Avicena Group, Inc., USA; The General Hospital Corporation
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9951097	A1	19991014	WO 1999-US7340		19990402
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2327095	AA	19991014	CA 1999-2327095		19990402
AU 9933803	A1	19991025	AU 1999-33803		19990402
AU 759467	B2	20030417			
EP 1065931	A1	20010110	EP 1999-915245		19990402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002510604	T2	20020409	JP 2000-541878		19990402
PRIORITY APPLN. INFO.:			US 1998-80459P	P	19980402
			US 1999-283267	A	19990401
			WO 1999-US7340	W	19990402

OTHER SOURCE(S): MARPAT 131:281583

AB The invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate, or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compds. in combination with neuroprotective agents can be used as therapeutically effective compns. against a variety of diseases of the nervous system, e.g. diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, **Parkinson**'s disease, stroke, Hungtington's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compds. which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compds. which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of ATP and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing nontransferable moieties which mimic the N-phosphoryl group.

IT **57-00-1 57-00-1D**, Creatine, analogs **67-07-2**, Creatine phosphate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(creatine compound-neuroprotective compound combination for treatment of nervous system disease)

RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 67-07-2 CAPLUS
CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:297312 CAPLUS
DOCUMENT NUMBER: 130:320858
TITLE: Nutritional supplement for cerebral metabolic insufficiencies
INVENTOR(S): Blass, John P.
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921565	A1	19990506	WO 1998-US18120	19980901
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2306875	AA	19990506	CA 1998-2306875	19980901
AU 9892139	A1	19990517	AU 1998-92139	19980901
AU 760140	B2	20030508		
EP 1032403	A1	20000906	EP 1998-944644	19980901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001521002	T2	20011106	JP 2000-517723	19980901
US 6537969	B1	20030325	US 2000-529091	20001020
US 2003176365	A1	20030918	US 2003-379816	20030304

PRIORITY APPLN. INFO.:

US 1997-63165P	P	19971024
WO 1998-US18120	W	19980901
US 2000-529091	A1	20001020

AB The present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate, or salt thereof, or a precursor of a Krebs cycle intermediate. Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, α-ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixts. thereof. Precursors of Krebs cycle intermediates are compds. converted by the body to form a Krebs cycle intermediate. The present invention also relates to administration of the pharmaceutical composition to treat an individual for a disorder involving impaired mitochondrial function and to improve cerebral function in an individual having impaired cerebral metabolism

IT **57-00-1**, Creatine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as adjuvant; nutritional supplements containing sugars and Krebs cycle intermediates for improving impaired mitochondrial functions)
RN 57-00-1 CAPLUS
CN Glycine, N-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:39:49 ON 19 MAY 2006)

FILE 'STNGUIDE' ENTERED AT 10:40:38 ON 19 MAY 2006

FILE 'HOME' ENTERED AT 10:40:45 ON 19 MAY 2006

FILE 'REGISTRY' ENTERED AT 10:40:53 ON 19 MAY 2006
L1 1 S CREATINE/CN
L2 1 S CREATINE PHOSPHATE/CN

FILE 'CAPLUS' ENTERED AT 10:41:58 ON 19 MAY 2006
L3 6248 S L1
L4 6248 S L1 FULL
L5 7256 S L2 FULL
L6 454 S (L4 OR L5) AND (GLUTAMATE EXCITOTOXITY OR BENOQUINONE OR NICO
L7 14 S L6 AND PARKINSON?

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.62	141.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-10.50

STN INTERNATIONAL LOGOFF AT 10:52:46 ON 19 MAY 2006